Arrowhead Research Corp. (NASDAQ:ARWR) shares traded up 3.3% during mid-day trading on Monday . The company traded as high as $8.00 and last traded at $7.75, with a volume of 921,962 shares trading hands. The stock had previously closed at $7.50.

A number of research analysts have recently issued reports on the company. William Blair assumed coverage on Arrowhead Research Corp. in a research report on Friday, August 19th. They set an “outperform” rating on the stock. Piper Jaffray Cos. decreased their target price on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 10th. Cantor Fitzgerald assumed coverage on Arrowhead Research Corp. in a research report on Wednesday, August 17th. They set a “buy” rating and a $15.00 target price on the stock. Jefferies Group reiterated a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. Finally, Chardan Capital assumed coverage on Arrowhead Research Corp. in a research report on Thursday, May 19th. They set a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.44.

The stock’s market cap is $474.46 million. The firm’s 50-day moving average price is $6.02 and its 200 day moving average price is $5.37.

Arrowhead Research Corp. (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. During the same quarter last year, the business earned ($0.27) earnings per share. The firm earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. The business’s revenue for the quarter was down 68.0% compared to the same quarter last year. Equities research analysts forecast that Arrowhead Research Corp. will post ($1.31) earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.